Financial Review: Evolent Health (EVH) vs. The Competition

Evolent Health (NYSE:EVH – Get Free Report) is one of 93 public companies in the “Healthcare Technology” industry, but how does it weigh in compared to its rivals? We will compare Evolent Health to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Insider and Institutional Ownership

42.4% of shares of all “Healthcare Technology” companies are held by institutional investors. 1.5% of Evolent Health shares are held by insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Evolent Health and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolent Health 1 3 10 0 2.64
Evolent Health Competitors 455 1537 2754 89 2.51

Evolent Health presently has a consensus price target of $6.04, indicating a potential upside of 23.61%. As a group, “Healthcare Technology” companies have a potential upside of 44.42%. Given Evolent Health’s rivals higher possible upside, analysts plainly believe Evolent Health has less favorable growth aspects than its rivals.

Profitability

This table compares Evolent Health and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evolent Health -21.67% -6.07% -1.23%
Evolent Health Competitors -750.30% -29.45% -15.32%

Earnings & Valuation

This table compares Evolent Health and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Evolent Health $1.88 billion -$534.51 million -1.08
Evolent Health Competitors $342.33 million -$24.15 million 12.80

Evolent Health has higher revenue, but lower earnings than its rivals. Evolent Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Evolent Health has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Evolent Health’s rivals have a beta of 1.11, meaning that their average share price is 11% more volatile than the S&P 500.

Summary

Evolent Health rivals beat Evolent Health on 7 of the 13 factors compared.

Evolent Health Company Profile

(Get Free Report)

Evolent Health, Inc. provides technology-enabled services to health plans and healthcare providers in the United States. The company helps clients manage care, coordinate services and support the delivery of healthcare, particularly for people with complex medical needs. Its offerings include specialty care management programs, clinical and administrative services, and technology that supports care decisions and operations. Evolent has focused on areas such as oncology, cardiology, musculoskeletal care and behavioral health.

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.